- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04061967
SMS-based Summons in Cervical Screening
Can SMS-reminders Result in Increased Participation in Cervical Screening?
Prevention of cervical cancer with cervical screening is one of the most successful screening activities in medicine. In Sweden, screening was implemented in the 1960s and has since prevented tens of thousands of women from having cervical cancer. Individual invitations to screening result in increased attendance therefore evaluating strategies for reaching women through invitations is particularly valuable. Women who regularly attend screening following an invitation reduce their risk of cervical cancer by as much as 90%. Of the women who are diagnosed with cervical cancer (about 550 women per year in Sweden), as many as 38% did not participate in the screening. Invitations for screening are sent to the entire population in Sweden aged 23-70. The current coverage of screening is 82.9%, which represents the proportion of women ages 23-70 who attend according to recommendations. In addition, many women are sporadic attenders who reduce their risk for cancer somewhat. The highest cancer risk is seen among those women who have never participated as well as women who have had a history of precancerous lesions or HPV infection but have not been followed-up. Cervical cancer is the first form of cancer for which there are approved molecular screening tests (HPV test). Unlike the older screening method (cytology), self-collected samples can be analyzed for HPV (the analysis method is so sensitive that it does not matter if the sample is not optimally taken).
Invitations and reminders about cervical screening are sent by letter to the woman's home address (about 3 million letters per year in Sweden). This strategy results in a waste of resources and has a negative environmental impact. Regarding reminders, we have seen in previous research that the effect is not optimal. When sending a physical reminder letter to women who have not participated in more than 10 years (current routine), only 2% of the women invited came for sampling. Reminders with SMS are now standard for many businesses in society, such as car testing or dental appointments. It is inexpensive, saves the environment and there are studies that suggest it is more effective than sending physical letters. In this study, we intend to investigate whether SMS reminders, electronic letters, and physical letters for screening lead to increased participation and thus to a higher proportion of detected, treatable precursors of cervical cancer compared to before.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-participation in the cervical screening program and sub-optimal follow-up after abnormalities or infection with a highly oncogenic HPV type detected in screening are the main risk factors for cervical cancer. Given this, It is important to reduce barriers to screening and facilitate participation in the screening program of cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations. Women who have been lost to follow-up can also be reached with self-sampling.
The purpose of this study is to investigate whether SMS reminders and electronic letters for screening attendance will increase participation compared to the current method where reminders are sent out with physical letters. In this study, women a with high risk of developing cervical cancer, due to not fully participating in screening or being followed up optimally, will be invited. Women are identified through registry linkages annually that examine screening history and status using a risk algorithm. Women receive an SMS or an electronic letter with an offer to request a self-sampling kit via the internet. Women with a higher risk for cervical cancer can be offered a self-sampling kit sent directly to their home address. The self-sampling kit comes with an instruction on how to take the sample and a postage-free answer envelope.
Submitted samples are analyzed with an approved and accredited method (Cobas 4800, Roche) that analyzes for HPV 16, HPV18 and other oncogenic HPV types. As the screening program changed the accredited HPV test in 2022 (to BD Onclarity), that test will be used from the timepoint of the change and onwards.
In the pilot of the study, follow-up is defined as follows:
- For those women who are at the highest risk (previous glandular cell changes without follow-up), all HPV-positive women are referred via SMS directly to a women's clinic for investigation. HPV-negative women in this group have no increased risk and receive a text message with a calming message.
- Women of an age above the screening program but who have either had a cell change that is not followed up or who have not participated at all in the last 10 years are treated in the same way as in paragraph 1.
- Finally, the women of screening age who have not taken a cell sample for more than 15 years are identified. This group receive an SMS and HPV-positive women are referred, via SMS, for renewed sampling by a specially trained so-called dysplasia midwife. The sample is now being analyzed for both cytology and HPV. If the woman is HPV positive in both tests and in the case of deviating cytology, the woman is referred to a women's clinic. In other cases a text message with a reassuring message is sent.
The study has the usual level of confidence (p <0.05 two-sided) and statistical power (80%) the ability to demonstrate an increase of participation by 3 times or more.
The protocol was piloted in the Region of Skåne in 2019 and then rolled out nationally in 2020.
The study is rolled out nationally with annual linkages to identify women with an excess risk for cervical cancer and an adaptive approach to reaching women with SMS, electronic letters, and physically letters with direct delivery of HPV self-sampling kits or an option to order a self-sampling kid (depending on risk). The study is coordinated centrally and each region has a contact person to whom women who need follow-up are referred.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miriam Elfström, PhD
- Phone Number: +46(0)703816277
- Email: Miriam.elfstrom@sll.se
Study Contact Backup
- Name: Helena Andersson, PhD
- Phone Number: +46-858581894
- Email: helena.andersson.1@ki.se
Study Locations
-
-
-
Jönköping, Sweden, 581 85
- Recruiting
- Southeast Region
-
Contact:
- Mirjam Våtz, Midwife
- Email: mirjam.vatz@rjl.se
-
Stockholm, Sweden, 112 18
- Recruiting
- Region of Stockholm-Gotland
-
Contact:
- Hanna Milerad, MD
- Phone Number: +46 (0) 70-490 98 28
- Email: hanna.milerad@regionstockholm.se
-
Uppsala, Sweden, 751 85
- Recruiting
- Region of Middle Sweden
-
Contact:
- Lovisa Bergengren, MD, PhD
- Phone Number: +46 (0) 73-310 45 56
- Email: lovisa.bergengren@regionorebrolan.se
-
-
Norrbotten
-
Luleå, Norrbotten, Sweden, 901 87
- Recruiting
- Northern Region
-
Contact:
- Viviann Mattsson, MD
- Email: viviann.mattsson@norrbotten.se
-
-
Skåne
-
Lund, Skåne, Sweden, 221 00
- Recruiting
- Southern Region
-
Contact:
- Christer Borgfeldt, MD, PhD
- Phone Number: +46 (0) 70-995 04 72
- Email: Christer.Borgfeldt@med.lu.se
-
-
Västra Götaland
-
Gothenburg, Västra Götaland, Sweden, 413 45
- Recruiting
- Western Region
-
Contact:
- Katarina Kylebäck, MD
- Email: katarina.kyleback@vgregion.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years.
Exclusion Criteria:
- No exclusion except those who do not consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: HPV self sampling test ordered
An invitation to order a HPV self sampling test through an online application will be sent by SMS or electronic letter.
|
2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured. 2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of women responding to summon
Time Frame: Measured from the date of the summons until 12 months after the summons
|
Participation rate in screening after summons.
|
Measured from the date of the summons until 12 months after the summons
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of positive screens
Time Frame: Measured from the date of the summons until 12 months after the summons
|
Screening test results
|
Measured from the date of the summons until 12 months after the summons
|
Rate of precursors of cancer
Time Frame: Measured from the date of the summons until 12 months after the summons
|
Cytologically and histopathologically confirmed percursors of cervical cancer.
|
Measured from the date of the summons until 12 months after the summons
|
Rate of cancer
Time Frame: Measured from the date of the summons until 12 months after the summons
|
Histopathologically confirmed cervical cancers.
|
Measured from the date of the summons until 12 months after the summons
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Miriam Elfström, PhD, Karolinska Institutet
Publications and helpful links
General Publications
- Elfstrom KM, Sundstrom K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Ohman D, Lamin H, Eklund C, Dillner J, Tornberg S. Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. Int J Cancer. 2019 Dec 1;145(11):3033-3039. doi: 10.1002/ijc.32374. Epub 2019 May 10.
- Wang J, Elfstrom KM, Borgfeldt C, Dillner J. A pilot study of risk-stratified cervical cancer screening. Open Res Eur. 2022 Sep 1;1:84. doi: 10.12688/openreseurope.13398.2. eCollection 2021.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Neoplasms
- Uterine Cervical Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Neoplasms by Site
- Uterine Neoplasms
- Uterine Cervical Diseases
- Genital Diseases, Female
- Genital Diseases
Other Study ID Numbers
- 2019-03166
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI); Department of Health and Human Services; Early... and other collaboratorsRecruitingColonic NeoplasmsUnited States, Canada, Australia
Clinical Trials on Sending of screening summon.
-
International Agency for Research on CancerEnrolling by invitation
-
Centre Psychothérapique de NancyGroupement Interrégional de Recherche Clinique et d'InnovationNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedLow Trauma Non Vertebral FractureFrance
-
Nantes University HospitalCompletedPatients at Risk for MelanomaFrance
-
Akdeniz UniversityRecruiting
-
Umeå UniversityKarolinska Institutet; Lund University; Göteborg UniversityEnrolling by invitationLynch Syndrome | Hereditary Breast and Ovarian Cancer Syndrome | Familial Breast Cancer | Hereditary Breast Cancer | Familial Colorectal CancerSweden
-
University of Medicine and Dentistry of New JerseyCenters for Medicare and Medicaid ServicesCompleted
-
University of PennsylvaniaCompleted
-
Universitätsklinikum Hamburg-EppendorfGerman Research FoundationCompletedDepression | Major Depressive DisorderGermany
-
University College London HospitalsCompleted